Hanmi Pharmaceutical's pharmaceutical ingredient (API) specialized subsidiary Hanmi Precision Chemical announced on the 19th that it has entered into a contract manufacturing agreement with LigaChem Biosciences, a leading corporation in the antibody-drug conjugate (ADC) field, and has begun preparations for the production of ADC intermediate substances.
ADC is a therapeutic technology that attaches drugs to antibodies to accurately deliver them only to cancer cells. The antibody and cytotoxic drug (payload) are linked by a linker, allowing the cytotoxic anticancer drug to act only on the targeted cancer cells. It is similar to a missile (antibody) accurately flying toward a target (cancer cell antigen) and detonating the warhead (drug).
Hanmi Precision Chemical produces the core intermediate substances of LigaChem Biosciences' ADC platform 'ConjuALL.'
Park Cheol-hyun, managing director of Hanmi Precision Chemical, said, "With the combination of our differentiated contract development and manufacturing organization (CDMO) capabilities and LigaChem Biosciences' innovative ADC technology, we expect to create a unique synergy. This contract signing will be a key to securing differentiated competitiveness in the ADC market and generating new growth momentum, beyond just a simple technological combination."